Compare Stocks: ABSI, ALKS, IOVA, and IMVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.33 -4.7%	$9.34	$2.24 ▼ $12.06	$1.43B	2.27	4.32 million shs	538,276 shs
ALKS Alkermes	$40.35 +3.2%	$45.34	$27.00 ▼ $55.67	$6.75B	0.32	2.14 million shs	108,773 shs
IMVT Immunovant	$28.21 +1.1%	$37.79	$17.02 ▼ $45.42	$5.83B	0.84	1.51 million shs	77,194 shs
IOVA Iovance Biotherapeutics	$14.33 +0.8%	$9.85	$1.76 ▼ $15.30	$6.52B	0.76	15.71 million shs	1.31 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	-3.96%	-5.21%	+8.03%	+6.20%	+124.10%
ALKS Alkermes	-1.64%	-5.69%	-14.73%	-24.76%	+22.35%
IMVT Immunovant	-2.82%	-12.92%	-25.92%	-28.39%	+59.52%
IOVA Iovance Biotherapeutics	-2.00%	+10.07%	+53.46%	+204.94%	+570.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.33 -4.7%	$9.34	$2.24 ▼ $12.06	$1.43B	2.27	4.32 million shs	538,276 shs
ALKS Alkermes	$40.35 +3.2%	$45.34	$27.00 ▼ $55.67	$6.75B	0.32	2.14 million shs	108,773 shs
IMVT Immunovant	$28.21 +1.1%	$37.79	$17.02 ▼ $45.42	$5.83B	0.84	1.51 million shs	77,194 shs
IOVA Iovance Biotherapeutics	$14.33 +0.8%	$9.85	$1.76 ▼ $15.30	$6.52B	0.76	15.71 million shs	1.31 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	-3.96%	-5.21%	+8.03%	+6.20%	+124.10%
ALKS Alkermes	-1.64%	-5.69%	-14.73%	-24.76%	+22.35%
IMVT Immunovant	-2.82%	-12.92%	-25.92%	-28.39%	+59.52%
IOVA Iovance Biotherapeutics	-2.00%	+10.07%	+53.46%	+204.94%	+570.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.80	Moderate Buy	$13.88	66.55% Upside
ALKS Alkermes	2.74	Moderate Buy	$54.47	35.01% Upside
IMVT Immunovant	2.58	Moderate Buy	$44.00	55.96% Upside
IOVA Iovance Biotherapeutics	2.62	Moderate Buy	$13.20	-7.89% Downside

Current Analyst Ratings Breakdown

Latest ABSI, ALKS, IOVA, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$15.00 ➝ $18.00
10/12/2026	ABSI Absci	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$14.00 ➝ $15.00
10/12/2026	ABSI Absci	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$16.00
10/8/2026	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$6.00 ➝ $11.00
10/2/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$14.00 ➝ $18.00
9/29/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/29/2026	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$9.00 ➝ $20.00
9/28/2026	ABSI Absci	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/24/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Positive

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	510.60	N/A	N/A	$1.26 per share	6.61
ALKS Alkermes	$1.48B	4.59	$1.70 per share	23.73	$11.02 per share	3.66
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.19 per share	N/A
IOVA Iovance Biotherapeutics	$324.97M	19.97	N/A	N/A	$1.76 per share	8.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/12/2026 (Estimated)
ALKS Alkermes	$241.66M	$0.38	105.92	168.11	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	11/9/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)

Latest ABSI, ALKS, IOVA, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ABSI Absci	-$0.1898	N/A	N/A	N/A	$0.70 million	N/A
11/9/2026	Q2 2027	IMVT Immunovant	-$0.73	N/A	N/A	N/A	$7.10 million	N/A
11/5/2026	Q3 2026	IOVA Iovance Biotherapeutics	-$0.0847	N/A	N/A	N/A	$115.53 million	N/A
10/28/2026	Q3 2026	ALKS Alkermes	-$0.0788	N/A	N/A	N/A	$463.35 million	N/A
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
ALKS Alkermes	0.82	2.30	1.85
IMVT Immunovant	N/A	7.27	7.27
IOVA Iovance Biotherapeutics	N/A	4.34	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
ALKS Alkermes	95.21%
IMVT Immunovant	47.08%
IOVA Iovance Biotherapeutics	77.03%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
ALKS Alkermes	4.59%
IMVT Immunovant	1.90%
IOVA Iovance Biotherapeutics	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	140	171.61 million	153.56 million	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
IMVT Immunovant	315	206.55 million	202.63 million	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable

ABSI, ALKS, IOVA, and IMVT Headlines

Recent News About These Companies

Iovance Biotherapeutics, Inc. (IOVA) - What Are Investment Firms Saying About This Stock?

October 14 at 2:15 AM | americanbankingnews.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock Has Average Price Target of $13.20

October 14 at 2:13 AM | marketbeat.com

30 U.S. stocks flashing Strong Buy ratings as earnings roll in

October 14 at 1:16 AM | seekingalpha.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Climb 6.6% After Analyst Upgrade

October 11, 2026 | americanbankingnews.com

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Expected to Rise, Robert W. Baird Analyst Says

October 10, 2026 | americanbankingnews.com

Iovance Expands Lifileucel Into Sarcoma: What SARATOGA Means for Investors

October 9, 2026 | tipranks.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.6% on Analyst Upgrade

October 9, 2026 | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Gets Price Target Increase from Robert W. Baird

October 8, 2026 | marketbeat.com

AVBCC Recognizes Iovance Biotherapeutics’ Dr. Fred Vogt with Inaugural Global Cancer Research & Innovation Award

October 7, 2026 | greenbaypressgazette.comG

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.2% - Here's Why

October 6, 2026 | marketbeat.com

Iovance: Buy Now Before Many Growth Catalysts Kick In

October 5, 2026 | seekingalpha.com

Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3

October 4, 2026 | finance.yahoo.com

Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook

October 3, 2026 | finance.yahoo.com

Why Is Iovance Biotherapeutics (NASDAQ:IOVA) Suddenly a Must-Watch Healthcare Stocks Name?

October 2, 2026 | kalkinemedia.comK

Iovance Biotherapeutics consensus price target increased by 34.74% to $13.06

October 2, 2026 | msn.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

October 2, 2026 | zacks.com

What is Zacks Research's Forecast for IOVA FY2026 Earnings?

October 2, 2026 | marketbeat.com

Iovance Biotherapeutics Names Noah Berkowitz CMO

October 1, 2026 | rttnews.com

IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook

October 1, 2026 | finance.yahoo.com

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

October 1, 2026 | globenewswire.com

HC Wainwright Brokers Boost Earnings Estimates for IOVA

October 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABSI, ALKS, IOVA, and IMVT Company Descriptions

Absci NASDAQ:ABSI

$8.33 -0.41 (-4.68%)

As of 10:15 AM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Alkermes NASDAQ:ALKS

$40.35 +1.27 (+3.24%)

As of 10:15 AM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Immunovant NASDAQ:IMVT

$28.21 +0.31 (+1.12%)

As of 10:15 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Iovance Biotherapeutics NASDAQ:IOVA

$14.33 +0.12 (+0.84%)

As of 10:15 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABSI, ALKS, IOVA, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABSI, ALKS, IOVA, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABSI, ALKS, IOVA, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABSI, ALKS, IOVA, and IMVT Company Descriptions

Absci NASDAQ:ABSI

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABSI, ALKS, IOVA, and IMVT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABSI, ALKS, IOVA, and IMVT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABSI, ALKS, IOVA, and IMVT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABSI, ALKS, IOVA, and IMVT Company Descriptions

Absci NASDAQ:ABSI

Alkermes NASDAQ:ALKS

Immunovant NASDAQ:IMVT

Iovance Biotherapeutics NASDAQ:IOVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools